Skip to main content
SpringerLink
Log in

Treating Osteoporosis with Bisphosphonates and Addressing Adherence

A Review of Oral Ibandronate

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Osteoporosis is a common, chronic condition, affecting approximately half of all postmenopausal Caucasian women in the US. Vertebral fractures occur as a result of osteoporosis and lead to increased hospitalisation and mortality, and adversely affect patient quality of life. The burden of osteoporosis on healthcare systems is expected to rise as the elderly population continues to grow. Yet there are many medications for preventing and treating osteoporosis.

Oral bisphosphonates are first-line treatment for osteoporosis, with demonstrated efficacy in increasing bone mineral density and reducing bone turnover, which reduces the incidence of fractures. However, adherence to medication is suboptimal, with approximately 40% of patients discontinuing treatment within 6 months. Recent reports have suggested simplifying the dosage regimen as a strategy to help address this issue.

Ibandronate is a potent, nitrogen-containing bisphosphonate which is administered once-monthly. Preclinical studies initially revealed the feasibility of extending the between-dose interval. Subsequent clinical studies have provided further evidence of the positive effects of extended-interval ibandronate administration in reducing the risk of vertebral fractures through increasing bone mineral density and reducing bone turnover without compromising bone quality. These studies have also demonstrated that ibandronate has a safety profile similar to placebo. Ibandronate has recently been approved for use in the US to treat postmenopausal osteoporosis.

This review summarises the efficacy and safety of once-monthly oral ibandronate and discusses the implications of such a treatment in primary care in the US.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Institutes of Health USA. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000; 17: 1–45

    Google Scholar 

  2. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992; 327: 620–7

    Article  PubMed  CAS  Google Scholar 

  3. Melton LJ III, Chrischilles EA, Cooper C, et al. Perspective: how many women have osteoporosis? J Bone Miner Res 1992; 7: 1005–10

    Article  PubMed  Google Scholar 

  4. Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151: 2026–32

    Article  PubMed  CAS  Google Scholar 

  5. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998; 128: 793–800

    PubMed  CAS  Google Scholar 

  6. Ensrud KE, Thompson DE, Cauley JA, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 2000; 48: 241–9

    CAS  Google Scholar 

  7. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159: 1215–20

    CAS  Google Scholar 

  8. Wasnich RD. Vertebral fracture epidemiology. Bone 1996; 18: 179–183S

    Article  Google Scholar 

  9. Kotowicz MA, Melton LJ III, Cooper C, et al. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 1994; 9: 599–605

    Article  PubMed  CAS  Google Scholar 

  10. Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919–23

    PubMed  CAS  Google Scholar 

  11. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375–82

    Article  PubMed  CAS  Google Scholar 

  12. Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7: 390–406

    CAS  Google Scholar 

  13. Heinemann DF. Osteoporosis: an overview of the National Osteoporosis Foundation clinical practice guide. Geriatrics 2000; 55: 31–6

    PubMed  CAS  Google Scholar 

  14. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003

    Google Scholar 

  15. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544–64

    PubMed  Google Scholar 

  16. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496–503

    Article  Google Scholar 

  17. ACOG Practice Bulletin Number 50. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Obstet Gynecol 2004; 103: 203–16

    Google Scholar 

  18. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005; 16: 229–38

    Article  PubMed  CAS  Google Scholar 

  19. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103–11

    Article  PubMed  CAS  Google Scholar 

  20. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82

    Article  PubMed  CAS  Google Scholar 

  21. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–52

    CAS  Google Scholar 

  22. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437–43

    CAS  Google Scholar 

  23. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–40

    CAS  Google Scholar 

  24. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9: 461–8

    CAS  Google Scholar 

  25. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91

    CAS  Google Scholar 

  26. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–41

    CAS  Google Scholar 

  27. Chesnut CG III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241–9

    Article  CAS  Google Scholar 

  28. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43–9

    Article  PubMed  CAS  Google Scholar 

  29. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48: 271–87

    Article  PubMed  CAS  Google Scholar 

  30. Unson CG, Siccion E, Gaztambide J, et al. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt) 2003; 12: 1037–45

    Article  CAS  Google Scholar 

  31. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555–67

    Article  PubMed  CAS  Google Scholar 

  32. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310

    Article  PubMed  CAS  Google Scholar 

  33. Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307–35

    Article  PubMed  Google Scholar 

  34. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453–60

    Article  PubMed  CAS  Google Scholar 

  35. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856–61

    Article  PubMed  Google Scholar 

  36. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003; 14: 259–62

    PubMed  CAS  Google Scholar 

  37. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am JMed 2003; 115: 209–16

    Google Scholar 

  38. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5: 859–62

    PubMed  Google Scholar 

  39. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14: 965–8

    Article  PubMed  CAS  Google Scholar 

  40. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003–8

    Article  PubMed  Google Scholar 

  41. Ettinger M, Gallagher R, Amonkar M, et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate [abstract]. Arthritis Rheum 2004; 50: S513

    Google Scholar 

  42. Bone Health and Osteoporosis: a report of the Surgeon General. Vol. 2005 [online]. Available from URL: http://www.hhs.gov/surgeongeneral/library/bonehealth/content.html [Accessed 2006 Jun 20]

  43. Simon JA, Beusterien KM, Hebborn A, et al. Women with postmenopausal osteoporosis express a preference for once-monthly versus once-weekly bisphosphonate treatment. Female Patient 2005; 30: 31–6

    Google Scholar 

  44. Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995; 56: 18–22

    PubMed  Google Scholar 

  45. Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003; 21: 153–8

    Article  PubMed  Google Scholar 

  46. Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002; 55: 809–17

    Article  PubMed  Google Scholar 

  47. Gold DT, Ettinger M, Gallagher R, et al. Medication burden among women with postmenopausal osteoporosis. Washington, DC: National Osteoporosis Foundation, 2005 Apr 5–10

    Google Scholar 

  48. Muhlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991; 6: 1003–11

    Article  PubMed  CAS  Google Scholar 

  49. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004; 15: 423–33

    Article  PubMed  CAS  Google Scholar 

  50. Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 2003; 25: 19–34

    Article  PubMed  CAS  Google Scholar 

  51. Bauss F, Schenk RK, Hort S, et al. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 2004; 50: 25–34

    Article  PubMed  CAS  Google Scholar 

  52. Bauss F, Wagner M, Hothorn LH. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 2002; 29: 990–8

    PubMed  CAS  Google Scholar 

  53. Bauss F, Lalla S, Endele R, et al. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 2002; 29: 2200–8

    PubMed  CAS  Google Scholar 

  54. Monier-Faugere MC, Friedler RM, Bauss F, et al. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993; 8: 1345–55

    Article  PubMed  CAS  Google Scholar 

  55. Monier-Faugere MC, Geng Z, Paschalis EP, et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 1999; 14: 1768–78

    Article  PubMed  CAS  Google Scholar 

  56. Smith SY, Recker RR, Hannan M, et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003; 32: 45–55

    Article  PubMed  CAS  Google Scholar 

  57. Burr DB, Miller L, Grynpas M, et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 2003; 33: 960–9

    Article  PubMed  CAS  Google Scholar 

  58. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996; 14: 158–70

    Article  PubMed  CAS  Google Scholar 

  59. Riis BJ, Ise J, von Stein T, et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001; 16: 1871–8

    Article  PubMed  CAS  Google Scholar 

  60. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12: 1–12

    CAS  Google Scholar 

  61. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315–22

    Article  PubMed  CAS  Google Scholar 

  62. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586–92

    Article  PubMed  CAS  Google Scholar 

  63. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231–6

    Article  PubMed  CAS  Google Scholar 

  64. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281–9

    Article  PubMed  CAS  Google Scholar 

  65. Heaney RP. Is the paradigm shifting? Bone 2003; 33: 457–65

    Article  PubMed  Google Scholar 

  66. Marcus R, Wong M, Heath H III, et al. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002; 23: 16–37

    Article  PubMed  CAS  Google Scholar 

  67. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051–6

    Article  PubMed  CAS  Google Scholar 

  68. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000; 160: 517–25

    Article  PubMed  CAS  Google Scholar 

  69. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189–99

    Article  PubMed  CAS  Google Scholar 

  70. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462–8

    Article  PubMed  CAS  Google Scholar 

  71. Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995; 90: 1889–90

    PubMed  CAS  Google Scholar 

  72. Naylor G, Davies MH. Oesophageal stricture associated with alendronic acid. Lancet 1996; 348: 1030–1

    Article  PubMed  CAS  Google Scholar 

  73. Cameron RB. Esophagitis dissecans superficialis and alendronate: case report. Gastrointest Endosc 1997; 46: 562–3

    Article  PubMed  CAS  Google Scholar 

  74. Levine J, Nelson D. Esophageal stricture associated with alendronate therapy. Am J Med 1997; 102: 489–91

    Article  PubMed  CAS  Google Scholar 

  75. Levine MAH. Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy. Pharmacoepidemiol Drug Saf 2000; 9: 367–70

    Article  PubMed  CAS  Google Scholar 

  76. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Manag Care Pharm 1998; 4: 488–92

    Google Scholar 

  77. Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997; 42: 281–8

    Article  PubMed  CAS  Google Scholar 

  78. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161: 107–10

    Article  PubMed  CAS  Google Scholar 

  79. Rothschild BM, Helbling ME. Alendronate (Fosamax) interactions with nonsteroidal anti-inflammatory agents: a dangerous combination [abstract]? Arthritis Rheum 2000; 43: S199

    Google Scholar 

  80. Delmas PD, Emkey R, Gilbride J, et al. Oral ibandronate has a similar gastrointestinal (GI) safety profile to placebo in patients with a history of GI disorders or receiving concomitant NSAIDS [abstract no. P267]. Osteoporos Int 2003; 14: S74

    Google Scholar 

  81. Miller PD, Drezner MK, Delmas PD, et al. Monthly oral ibandronate is at least as effective as oral daily ibandronate in postmenopausal osteoporosis: 1-year results from MOBILE [abstract no. F408]. J Bone Miner Res 2004; 19: S94

    Google Scholar 

  82. Cooper C, Emkey RD, McDonald RH, et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 4609–15

    Article  PubMed  CAS  Google Scholar 

  83. Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996; 19: 527–33

    Article  PubMed  CAS  Google Scholar 

  84. McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004; 19: 11–8

    Article  PubMed  CAS  Google Scholar 

  85. Tanko LB, Felsenberg D, Czerwinski E, et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 2003; 254: 159–67

    Article  PubMed  CAS  Google Scholar 

  86. Libow LS. Geriatrics in the United States baby boomers' boon? N Engl J Med 2005; 352: 750–2

    Article  PubMed  CAS  Google Scholar 

  87. Gourlay M. Osteoporosis management: out of subspecialty practice and into primary care. Am Fam Physician 2004; 70: 1219–20

    PubMed  Google Scholar 

  88. Melton LJ III. Epidemiology of spinal osteoporosis. Spine 1997; 22: 2–11S

    Google Scholar 

  89. Zizic TM. Pharmacologic prevention of osteoporotic fractures. Am Fam Physician 2004; 70: 1293–300

    PubMed  Google Scholar 

  90. Jaglal SB, McIsaac WJ, Hawker G, et al. Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process. Osteoporos Int 2003; 14: 672–6

    Article  PubMed  Google Scholar 

  91. Newton KM, Lacroix AZ, Leveille SG, et al. The physician's role in women's decision making about hormone replacement therapy. Obstet Gynecol 1998; 92: 580–4

    Article  PubMed  CAS  Google Scholar 

  92. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 1117–23

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Osteoporosis Research Group, University of Washington Medical Center, 1107 NE 45th Street, Suite 440, Seattle, Washington, 98195, USA

    Charles H. Chesnut III

Authors
  1. Charles H. Chesnut III
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chesnut, C.H. Treating Osteoporosis with Bisphosphonates and Addressing Adherence. Drugs 66, 1351–1359 (2006). https://doi.org/10.2165/00003495-200666100-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666100-00004

Keywords

Search

Navigation